Merck Joins KRAS Stampede In Deal With Otsuka Affiliates
Executive Summary
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.
You may also be interested in...
Asia Deal Watch: BeiGene Leaps Into New Year By Licensing DKK1 Antibody Candidate
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.
Deal Watch: Early 2020 Deal-Making Boom Starts With Third Bayer/Evotec R&D Alliance
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
Lilly Taps Loxo Execs To Bring Back That Biotech Feeling
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Need a specific report? 1000+ reports available
Buy Reports
